Improving opportunities for effective management of gastro-oesophageal reflux disease

Digestive and Liver Disease

Volumn 33, Issue 8, 2001, Pages 720-730

  Vigneri, S ^a   Tonini, M ^a,b   Scarpignato, C ^c   Savarino, V ^d  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Esomeprazole; Gastro oesophageal reflux disease; Proton pump inhibitors

Indexed keywords

CISAPRIDE; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SUCRALFATE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; HUMAN; MOLECULE; STOMACH ACID SECRETION; STOMACH PH; SYMPTOM;

ANTI-ULCER AGENTS; BIOLOGICAL AVAILABILITY; ESOPHAGITIS; GASTRIC MUCOSA; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; ISOMERISM; OMEPRAZOLE; PROTON PUMPS; TREATMENT OUTCOME;

EID: 0035193239     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(01)80051-7     Document Type: Article

References (76)

1. Epidemiology and natural history of gastro-oesophageal reflux disease
2. An evidence-based appraisal of reflux disease management: The Genval Workshop Report
3. Epidemiology of reflux disease and reflux esophagitis
4. Gastroesophageal reflux disease in primary care in Europe: Clinical presentation and endoscopic findings
5. Heartburn requiring frequent antacid use may indicate significant illness
6. Three-year follow-up of patients with gastro-oesophageal reflux disease
7. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients
8. The natural history, prevalence and incidence of reflux esophagitis
9. Incidence of esophageal stricture formation in patients with complicated gastroesophageal reflux disease
10. Effective maintenance treatment of reflux esophagitis with low dose lansoprazole: A randomised, double-blind, placebo controlled trial
11. Gastro-oesophageal reflux disease in primary care: An international study of different strategies with omeprazole
12. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time
13. Functional dyspepsia and irritable bowel syndrome: Is there a common pathophysiological basis?
14. Clinical esophageal pH recording: A technical review for practice guideline development
15. Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining therapeutic response
16. Omeprazole as diagnostic tool in gastroesophageal reflux disease
17. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease
18. The clinical and economic value of short course of Omeprazole in patients with noncardiac chest pain
19. The symptom index: Differential usefulness in suspected acid-related complaints of heartburn and chest pain
20. Symptom index as a marker of gastro-oesophageal reflux disease
21. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans
22. Sensitivity of esophageal mucosa to pH in gastroesophageal reflux disease
23. Segmental acid sensitivity of the esophagus in patients with endoscopy-negative GERD
24. Reflux symptoms relief with omeprazole in patients without unequivocal oesophagitis
25. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease
26. Drug therapy for reflux esophagitis
27. Treating the symptoms of gastroesophageal reflux disease: A double blind comparison of omeprazole and cisapride
28. Heartburn treatment in primary care: Randomised, double blind study for 8 weeks
29. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - The "sensitive oesophagus"
30. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease
31. Omeprazole 10 mg once daily, omeprazole 20 mg once daily or ranitidine 150 mg twice daily, evaluated as initial therapy for the relief of symptoms of gastroesophageal reflux in general public
32. Omeprazole in the long term treatment of gastroesophageal reflux disease. A double-blind randomized dose finding study
33. Predictive factors of the long-term outcome in gastroesophageal reflux disease: Six year follow up of 107 patients
34. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux
35. Maintenance treatment for gastro-oesophageal reflux disease: A placebo controlled evaluation of 10 mg omeprazole once daily in general practice
36. Appropriate acid suppression for the management of gastro-oesophageal reflux disease
37. Shortcomings of the first-generation proton pump inhibitors
38. Esomeprazole
39. Improving on PPI-based therapy of GERD
40. The symptom-relieving effect of esomeprazole 40 mg daily in patients with heartburn
41. The symptom-association probability: An improved method for symptom analysis of 24-hour esophageal data
42. Esomeprazole 20 mg maintains symptom control in endoscopy-negative GERD: A controlled trial of "on demand" therapy for 6 months
43. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative GERD: A placebo controlled trial of on-demand therapy for 6 months
44. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
45. Proton pump inhibitors, pharmacology and rationale for use in gastrointestinal disorders
46. Omeprazole: A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs
47. Proton pump inhibitors in acid-related disease
48. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease
49. Pantoprazole: A review of its pharmacological properties and therapeutic use in acid-related disorders
50. Rabeprazole: A proton pump inhibitor for the treatment of acid-related disorders
51. Lansoprazole: An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders
52. Lansoprazole: A comprehensive review
53. Health-related quality of life of patients with acute erosive reflux esophagitis
54. The impact of gastroesophageal reflux disease on health-related quality of life
55. Choice of long-term strategy for the management of patients with severe esophagitis: A cost-utility analysis
56. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
57. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole 40 mg
58. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg
59. Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitors
60. Esomeprazole provides improved acid control versus omeprazole in patients with symptoms of gastro-oesophageal reflux disease
61. Esomeprazole 40 mg provides more effective acid control than omeprazole 40 mg
62. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomised controlled trial
63. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomised trial
64. Rolling review: Gastroesophageal reflux disease
65. Audit of reflux oesophagitis at 4 years
66. Gastroesophageal reflux disease
67. A comparison of five maintenance therapies for reflux esophagitis
68. 2-receptor antagonist
69. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: A cost-effectiveness analysis
70. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia
71. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis: A 6-month, randomized double-blind, placebo controlled study of efficacy and safety
72. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux of efficacy and safety
73. Safety and efficacy of long term esomeprazole therapy in patients with healed erosive esophagitis
74. Safety of long-term treatment with a new PPI, esomeprazole in GERD patients
75. Gastro-oesophageal reflux and Helicobacter pylori
76. Non erosive reflux disease: The real problem in gastro-oesophageal reflux disease